Outcome of the Board Meeting held on 8 November 2025 - Unaudited Standalone Financial Results of the Company for the second quarter and half year ended 30 September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Terce Laboratories reported Q2 FY26 revenue from operations of Rs 1,292.63 lakhs, down about 2.8% from Rs 1,330.12 lakhs in Q2 FY25. Net profit for the quarter stood at Rs 140.36 lakhs (EPS Rs 1.89) versus Rs 148.22 lakhs (EPS Rs 2.00) a year ago, a decline of around 5%. For the half year, revenue fell to Rs 2,377.99 lakhs from Rs 2,519.00 lakhs (-5.6% YoY), while net profit was Rs 136.01 lakhs vs Rs 140.46 lakhs. The company swung back to profitability after posting a small loss of Rs 4.35 lakhs in Q1 FY26. The statutory auditor M.A. Shah & Co. issued an unmodified (clean) limited review report with no qualifications, and there were no exceptional items. Cash flow from operations turned positive at Rs 101.06 lakhs compared with a negative Rs 215.50 lakhs in H1 FY25.
The results are mixed — top-line continues to shrink year-on-year and bottom-line is marginally lower, which may weigh on sentiment. However, the strong sequential recovery from Q1's loss, improving operating cash flow, and clean auditor report offer some comfort for shareholders.